|
Neonatal Intensive Care Drug Manual
|
| bet | 49/654 | | Sana | 03.01.2022 | | Hajmi | 1,5 Mb. | | #14803 |
Amoxycillin
Revision Date : 16-11-2020
|
Approved : TC, KOH
|
Alert
|
S4 – High risk medicine.
Antimicrobial Stewardship Team recommends this drug is listed as unrestricted.
|
Indication
|
Directed treatment of infections caused by
susceptible gram positive (including Streptococcus species, Enterococcus faecalis and Listeria monocytogenes) and
susceptible gram negative bacteria (some strains of Escherichia coli, non-beta-lactamase-producing Haemophilus influenzae, Neisseria meningitidis, non-penicillinase-producing strains of Proteus and Salmonellae).
Empiric treatment of suspected early onset sepsis including meningitis, with an aminoglycoside.
|
Action
|
Bactericidal – inhibits synthesis of the bacterial cell wall. Amoxicillin is hydrolysed by beta-lactamases and therefore not effective against penicillinase-producing bacteria.
|
Drug Type
|
Antibacterial – semi-synthetic, bactericidal aminopenicillin
|
Trade Name
|
Alphamox Suspension [Alphapharm], Amoxil Paediatric Drops [Aspen], Amoxil Parenteral [Aspen], Amoxil Syrup Forte Sugar Free [Aspen], Amoxil Syrup Sugar Free [Aspen], Amoxycillin Sandoz [Sandoz], APO-Amoxycillin [Apotex], Bgramin [Ascent Pharma], Chemmart Amoxycillin [Apotex], Cilamox Sugar Free Syrup [Aspen Pharma], Fisamox [Aspen], Ibiamox [Willow], Maxamox [Sandoz], Ranmoxy Granules [Ranbaxy], Terry White Chemists Amoxycillin [Apotex]
|
Presentation
|
IV: Amoxicillin sodium 500 mg and 1 g vials.
Oral: Syrup 125 mg/5 mL and 250 mg/5 mL; Paediatric drops 100 mg/mL.
|
|
|
| |
